NDAINTRAVITREALINJECTABLEPriority Review
Approved
Nov 2007
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Data completeness
5/8 — Partial
Priority Review
Drug Shortage Active
TRIESENCE is currently in shortage. Reason: Limited Availability. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
TRIESENCE (triamcinolone acetonide) by Design Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for diabetic macular edema, acute gout. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIESENCE is a corticosteroid hormone receptor agonist administered via intravitreal injection for diabetic macular edema and acute gout. The drug works by binding to corticosteroid receptors to reduce inflammation and edema in the eye. Approved in 2007, it represents a targeted anti-inflammatory approach to sight-threatening retinal conditions.
Peak3.6 years to LOE
Product is in peak lifecycle stage but faces significant competitive pressure (score: 8/10) with limited publicly available sales data, suggesting a specialized market with moderate commercial infrastructure.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (2)
Clinical Trials (15)
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Started Oct 2020
40 enrolled
Drug-Drug Interaction
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Started Mar 2018
325 enrolled
Macular EdemaRetinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2017
460 enrolled
Macular EdemaRetinal Vein Occlusion
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Started Nov 2015
0UveitisCystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2015
46 enrolled
Macular EdemaRetinal Vein Occlusion
Worked on TRIESENCE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.